Samlyn Capital LLC has recently announced that it has increased stake in Satsuma Pharmaceuticals Inc. (NASDAQ:STSA) by 5.33%. After grabbing 2.94 million shares, the institutional investor is now in possession of 0.15 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 9.32% having worth around $15.25 million. Moreover, Columbia Management Investment Ad increased its share by 5108.0 to have a control over 0.76 million shares. And Dimensional Fund Advisors LP raised its holdings to 39731.0 shares by acquiring 0.28 million shares or 0.88% of the stake.
Satsuma Pharmaceuticals Inc. (STSA) concluded trading on 11/17/22 at a closing price of $0.62, with 2.97 million shares of worth about $1.84 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.77% during that period and on Thursday the price saw a gain of about 1.57%. Currently the company’s common shares owned by public are about 31.86M shares, out of which, 27.97M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the STSA stock and their offered price forecasts bring an average price target of $5.20. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $17.00 and could fall to a lowest price of $1.00. The stock’s current price level is 96.08% above of average price target set by the analysts, while a rise to estimated low would result in gain of 38.0% for the stock. However, touching the estimated high of $17.00 would mean a gain of 96.35% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 16,126 shares in 3 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, Columbia Small Cap Value Fund I, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Satsuma Pharmaceuticals Inc. Vanguard Total Stock Market Index is currently holding 0.51 million shares of worth totaling $2.65 million. The company recently came buying 0.0 shares which brought its stake up to 1.62% of the company’s outstanding shares. Columbia Small Cap Value Fund I bought 1100.0 shares, after which its hold over company’s outstanding shares expand to 1.55%, leaving 0.49 million shares with the mutual fund that have a worth of about $2.53 million. Vanguard Extended Market Index Fu, after buying 0.34 million shares, have now control over 1.07% of the stake in the company. It holds 0.23 million shares of worth $1.74 million.
Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) started trading at $0.6625, above $0.05 from concluding price of the previous day. However, the stock later moved at a day high price of 0.6600, or with a gain of 1.57%. Stock saw a price change of -85.35% in past 5 days and over the past one month there was a price change of -88.26%. Year-to-date (YTD), STSA shares are showing a performance of -86.23% which decreased to -89.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $8.08 during that period. The average intraday trading volume for Satsuma Pharmaceuticals Inc. shares is 522.55K. The stock is currently trading -85.26% below its 20-day simple moving average (SMA20), while that difference is down -88.62% for SMA50 and it goes to -86.53% lower than SMA200.
Samlyn Capital LLC acquired 2.94 million shares of Satsuma Pharmaceuticals Inc. having value of about $15.25 million. Data submitted at the U.S SEC by Samlyn Capital LLC revealed that the firm now holds 0.15 million shares in the company valued at close to $92408.52, or have control over 5.33% stake in the company. Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) currently have 31.86M outstanding shares and institutions hold larger chunk of about 69.70% of that. Holding of mutual funds in the company is about 51.28% while other institutional holders and individual stake holders have control over 8.63% and 43.99% of the stake respectively.
The stock has a current market capitalization of $21.44M. It has posted earnings per share of -$1.98 in the same period. It has Quick Ratio of 10.10 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for STSA, volatility over the week remained 13.53% while standing at 9.95% over the month.
Analysts are in expectations that Satsuma Pharmaceuticals Inc. (STSA) stock would likely to be making an EPS of -$0.54 in the current quarter, while forecast for next quarter EPS is -$0.43 and it is -$1.47 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.57 which is -$0.52 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.42 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 35.80% while it is estimated to increase by 25.80% in next year.
Analysts at 6 brokerage firms have issued recommendations for the Satsuma Pharmaceuticals Inc. (STSA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 6 Wall Street analysts, 3 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by SVB Leerink on October 10, 2022 offering an Outperform rating for the stock and assigned a target price of $15 to it. Coverage by Ladenburg Thalmann stated Satsuma Pharmaceuticals Inc. (STSA) stock as a Buy in their note to investors on August 31, 2022, suggesting a price target of $16 for the stock. On June 22, 2021, Mizuho Upgrade their recommendations, while on April 26, 2021, Credit Suisse Resumed their ratings for the stock with a price target of $6.50. Stock get a Neutral rating from Credit Suisse on March 02, 2021.